

N OIPE

CRF Errors Corrected by the STS Systems Branch

Serial Number: 09/832,899

CRF Processing Date: _____
Edited by: _____
Verified by: _____ (STIC staff)

- ☐ Changed a file from non-ASCII to ASCII
- ☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.
- ☐ Edited a format error in the Current Application Data section, specifically: **ENTERED**
- ☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other _____
- ☐ Added the mandatory heading and subheadings for "Current Application Data".
- ☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.
- ☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically: _____
- ☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were: _____
- ☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited: _____
- ☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
- ☐ Inserted colons after headings/subheadings. Headings edited included: _____
- ☐ Deleted extra, invalid, headings used by an applicant, specifically: _____
- ☒ Deleted: ☒ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file;
☐ page numbers throughout text; ☐ other invalid text, such as _____
- ☐ Inserted mandatory headings, specifically: _____
- ☐ Corrected an obvious error in the response, specifically: _____
- ☐ Edited identifiers where upper case is used but lower case is required, or vice versa.
- ☐ Corrected an error in the Number of Sequences field, specifically: _____
- ☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
- ☐ Deleted **ending** stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____
- ☐ Other: _____

*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

3/1/95

OIPE

RAW SEQUENCE LISTING

DATE: 05/03/2001

PATENT APPLICATION: US/09/832,899

TIME: 16:19:07

Input Set : A:\Cpg.pto

Output Set: N:\CRF3\05032001\I832899.raw

```

4 <110> APPLICANT: TRANSGENE S.A.
6 <120> TITLE OF INVENTION: Poxvirus with targeted infection specificity
8 <130> FILE REFERENCE: D18836
C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/832,899
C--> 10 <141> CURRENT FILING DATE: 2001-04-12
10 <150> PRIOR APPLICATION NUMBER: EP 00 44 0109
11 <151> PRIOR FILING DATE: 2000-04-14
13 <150> PRIOR APPLICATION NUMBER: EP 01 44 0009
14 <151> PRIOR FILING DATE: 2001-01-22
16 <150> PRIOR APPLICATION NUMBER: US 60/246 080
17 <151> PRIOR FILING DATE: 2000-11-07
19 <160> NUMBER OF SEQ ID NOS: 21
21 <170> SOFTWARE: PatentIn Ver. 2.1
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 24
25 <212> TYPE: DNA
26 <213> ORGANISM: Artificial Sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer to
30     amplify the MVA 138L gene and flanking region
32 <400> SEQUENCE: 1
33 cagactggac ggcgtccata tgag                                24
36 <210> SEQ ID NO: 2
37 <211> LENGTH: 61
38 <212> TYPE: DNA
39 <213> ORGANISM: Artificial Sequence
41 <220> FEATURE:
42 <221> NAME/KEY: gene
43 <222> LOCATION: Complement((1)..(61))
45 <220> FEATURE:
46 <223> OTHER INFORMATION: Description of Artificial Sequence: antisens PCR
47     primer to amplify the 3' end of MVA 138L gene and
48     3' flanking region
50 <400> SEQUENCE: 2
51 cattttttaa gtatagaata aaagatcccg ggagtacat cgtgattctt accagatatt 60
52 a                                                                61
55 <210> SEQ ID NO: 3
56 <211> LENGTH: 61
57 <212> TYPE: DNA
58 <213> ORGANISM: Artificial Sequence
60 <220> FEATURE:
61 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer to
62     amplify E. coli gpt gene and H5R promoter
64 <220> FEATURE:
65 <221> NAME/KEY: gene
66 <222> LOCATION: (1)..(61)
68 <400> SEQUENCE: 3

```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/832,899

DATE: 05/03/2001
TIME: 16:19:07

Input Set : A:\Cpg.pto
Output Set: N:\CRF3\05032001\I832899.raw

```

69 taatatctgg taagaatcac gatggtactc ccgggatctt ttattctata cttaaaaaat 60
70 g 61
73 <210> SEQ ID NO: 4
74 <211> LENGTH: 35
75 <212> TYPE: DNA
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <223> OTHER INFORMATION: Description of Artificial Sequence: antisense PCR
80 primer to amplify E. coli GPT gene and pH5R
81 promoter
83 <400> SEQUENCE: 4
84 ggggttaatt aaggaagtta aaaagaacaa cgccc 35
87 <210> SEQ ID NO: 5
88 <211> LENGTH: 38
89 <212> TYPE: DNA
90 <213> ORGANISM: Artificial Sequence
92 <220> FEATURE:
93 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer to
94 amplify the upstream region of MVA 138L gene.
96 <400> SEQUENCE: 5
97 gggggaattc gagcttatag cgtttagttc aggtacgg 38
100 <210> SEQ ID NO: 6
101 <211> LENGTH: 44
102 <212> TYPE: DNA
103 <213> ORGANISM: Artificial Sequence
105 <220> FEATURE:
106 <223> OTHER INFORMATION: Description of Artificial Sequence: antisense PCR
107 primer to amplify the upstream region of the MVA
108 138L gene
110 <400> SEQUENCE: 6
111 ggggaagctt ttaaagtaca gattttagaa actgacactc tgcg 44
114 <210> SEQ ID NO: 7
115 <211> LENGTH: 68
116 <212> TYPE: DNA
117 <213> ORGANISM: Artificial Sequence
119 <220> FEATURE:
120 <223> OTHER INFORMATION: Description of Artificial Sequence: antisense
121 primer to amplify the upstream region of the MVA
122 138L gene
124 <400> SEQUENCE: 7
125 ggggaagctt caagagcggc acggtcccg ccgctgcgac gttcaggagg accaaggcaa 60
126 ccacgaac 68
129 <210> SEQ ID NO: 8
130 <211> LENGTH: 31
131 <212> TYPE: DNA
132 <213> ORGANISM: Artificial Sequence
134 <220> FEATURE:
135 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer to
136 amplify the MVA 138L gene and its downstream

```

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/832,899

DATE: 05/03/2001
 TIME: 16:19:07

Input Set : A:\Cpg.pto
 Output Set: N:\CRF3\05032001\I832899.raw

```

137      region
139 <400> SEQUENCE: 8
140 ggggaagctt atggacggaa ctcttttccc c          31
143 <210> SEQ ID NO: 9
144 <211> LENGTH: 37
145 <212> TYPE: DNA
146 <213> ORGANISM: Artificial Sequence
148 <220> FEATURE:
149 <223> OTHER INFORMATION: Description of Artificial Sequence: antisense PCR
150      primer to amplify the MVA 138L gene and its
151      downstream region
153 <400> SEQUENCE: 9
154 gggggaattc gcttatcggt atcggtttta gcttctg          37
157 <210> SEQ ID NO: 10
158 <211> LENGTH: 68
159 <212> TYPE: DNA
160 <213> ORGANISM: Artificial Sequence
162 <220> FEATURE:
163 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer to
164      amplify SM3 scFv sequence
166 <400> SEQUENCE: 10
167 cgcagagtgt cagtttctaa aatctgtact ttaaattggtg cagctgcagg agtctggagg 60
168 aggccttg          68
171 <210> SEQ ID NO: 11
172 <211> LENGTH: 58
173 <212> TYPE: DNA
174 <213> ORGANISM: Artificial Sequence
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Description of Artificial Sequence: antisense PCR
178      primer to amplify the SM3 scFv sequence
180 <400> SEQUENCE: 11
181 gatcgtcatc tccggggaaa agagttccgt ccacagttt ggttcctcca ccgaacac 58
184 <210> SEQ ID NO: 12
185 <211> LENGTH: 57
186 <212> TYPE: DNA
187 <213> ORGANISM: Artificial Sequence
189 <220> FEATURE:
190 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer to
191      amplify the SM3 scFv sequence
193 <400> SEQUENCE: 12
194 cctgaacgtc gcagcggcgg gagccgtgcc gctcttggtg cagctgcagg agtctgg 57
197 <210> SEQ ID NO: 13
198 <211> LENGTH: 111
199 <212> TYPE: DNA
200 <213> ORGANISM: Artificial Sequence
202 <220> FEATURE:
203 <223> OTHER INFORMATION: Description of Artificial Sequence: sequence of
204      the synthetic p11k7.5 promoter
206 <400> SEQUENCE: 13

```

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/832,899

DATE: 05/03/2001
 TIME: 16:19:07

Input Set : A:\Cpg.pto
 Output Set: N:\CRF3\05032001\I832899.raw

```

207 ataaaaatat agtagaattt catttgtttt ttctatgct ataaatagga tccgataaag 60
208 tgaaaaataa ttctaattta ttgcacggtg aggaagtaga atcataaaga a 111
211 <210> SEQ ID NO: 14
212 <211> LENGTH: 53
213 <212> TYPE: DNA
214 <213> ORGANISM: Artificial Sequence
216 <220> FEATURE:
217 <223> OTHER INFORMATION: Description of Artificial Sequence:PCR primer to
218 amplify the pllk7.5 promoter
220 <400> SEQUENCE: 14
221 gggggatccc cggggctgca gaagcttttc ttatgattc tacttcccta ccg 53
224 <210> SEQ ID NO: 15
225 <211> LENGTH: 50
226 <212> TYPE: DNA
227 <213> ORGANISM: Artificial Sequence
229 <220> FEATURE:
230 <223> OTHER INFORMATION: Description of Artificial Sequence: antisense PCR
231 primer to amplify the pllk7.5 promoter
233 <400> SEQUENCE: 15
234 ggggggagat ctaagcttgt cgacataaaa atatagtaga atttcatttg 50
237 <210> SEQ ID NO: 16
238 <211> LENGTH: 77
239 <212> TYPE: DNA
240 <213> ORGANISM: Artificial Sequence
242 <220> FEATURE:
243 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
244 sequence
246 <400> SEQUENCE: 16
247 gatggtgaca gggggaatgg caagcaagtg ggatctcgag ttgggtgact ttggtgacag 60
248 atactactgt gtttaag 77
251 <210> SEQ ID NO: 17
252 <211> LENGTH: 85
253 <212> TYPE: DNA
254 <213> ORGANISM: Artificial Sequence
256 <220> FEATURE:
257 <223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
258 sequence
260 <400> SEQUENCE: 17
261 gatccttaaa cacagtagta tctgtcacca aagtcaccca actcgagatc ccacttgctt 60
262 gccattcccc ctgtcaccat ctgca 85
265 <210> SEQ ID NO: 18
266 <211> LENGTH: 32
267 <212> TYPE: DNA
268 <213> ORGANISM: Artificial Sequence
270 <220> FEATURE:
271 <223> OTHER INFORMATION: Description of Artificial Sequence:PCR primer to
272 amplify the 5' F13L flanking region of MVA
274 <400> SEQUENCE: 18
275 gagaggatcc gggatatctag ccacagtaaa tc 32

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/832,899

DATE: 05/03/2001

TIME: 16:19:07

Input Set : A:\Cpg.pto

Output Set: N:\CRF3\05032001\I832899.raw

```

278 <210> SEQ ID NO: 19
279 <211> LENGTH: 32
280 <212> TYPE: DNA
281 <213> ORGANISM: Artificial Sequence
283 <220> FEATURE:
284 <223> OTHER INFORMATION: Description of Artificial Sequence:Description of
285     Artificial Sequence :antisense PCR primer to
286     amplify the 5' F13L flanking region of MVA
288 <400> SEQUENCE: 19
289 ttctgaattc ggaatctgta ttctcaatac cg                      32
292 <210> SEQ ID NO: 20
293 <211> LENGTH: 33
294 <212> TYPE: DNA
295 <213> ORGANISM: Artificial Sequence
297 <220> FEATURE:
298 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer to
299     amplify the 3' F13L flanking region of MVA
301 <400> SEQUENCE: 20
302 atctgaattc gtggagatga tgatagttta agc                      33
305 <210> SEQ ID NO: 21
306 <211> LENGTH: 34
307 <212> TYPE: DNA
308 <213> ORGANISM: Artificial Sequence
310 <220> FEATURE:
311 <223> OTHER INFORMATION: Description of Artificial Sequence: antisense PCR
312     primer to amplify the 3' F13L flanking region of
313     MVA
315 <400> SEQUENCE: 21
316 aacaggatcc cttatacatc ctgttctatc aacg                      34

```

VERIFICATION SUMMARY

DATE: 05/03/2001

PATENT APPLICATION: US/09/832,899

TIME: 16:19:08

Input Set : A:\Cpg.pto

Output Set: N:\CRF3\05032001\I832899.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No

L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date